Is the era of prostatic specific antigen over?;¿Ha pasado la época del antígeno prostático específico?

Medicina Clinica

Volumn 126, Issue 15, 2006, Pages 579-580

  Morote Robles, Juan ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

EDITORIAL; HUMAN; BLOOD; CLINICAL TRIAL; MALE; PROGNOSIS; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY;

CLINICAL TRIALS; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33745207560     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13087700     Document Type: Editorial

References (21)

1. Morote J, Ruibal A. El antígeno prostático específico, nuevo marcador tumoral. Med Clin (Barc). 1985;85:801-4.
2. Morote J, Ruibal A, Palou J. Evaluation of prostatic specific antigen and prostatic acid phosphatase specificity: study of false positive values. Int J Biol Markers. 1986;1:141-6.
3. Catalona W, Richie J, Ahmann F, Hudson M, Scardino P, Flanigan R, et al. Comparison of digital rectal examination and serum prostatic specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol. 1994;151:1283-90.
4. Schmid H, Reisen W, Prikler L. Update on screening for prostate cancer with prostate-specific antigen. Critical Reviews in Oncology/Hematology. 2004;50:71-8.
5. Boyle P. Screening for prostate cancer: have you had your cholesterol measured? BJU Int. 2003;92:191-9.
6. Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level up to 4.0 ng per milliliter. N Engl J Med. 2004;350:2239-46.
7. Stamey T, Caldwell M, McNeal J, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the Unites States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172:1297-301.
8. Morote J, Raventós C, Lorente J, López M, Encabo G, Torres ID, et al. Comparison of percent free PSA and PSA density as method to enhance PSA specificity in early prostate cancer detection in men with normal rectal examination and PSA between 4.1 a 10 ng/ml. J Urol. 1997;158:502-4.
9. Morote J, Raventos C, Lorente J, López M, Encabo G, De Torres I, et al. Clinical usefulness of percent free PSA in the diagnosis and staging of prostate cancer. Int J Cancer. 1997;71:756-9.
10. Morote J. La cuantificación de la isoforma compleja del antígeno prostático específico (PSAc). Un nuevo reto en la era del PSA. Med Clin (Barc). 2004;122:241-4.
11. Catalona W, Loeb S. The PSA era is not over for prostate cancer. Eur Urol. 2005;48:541-5.
12. Catalona W, Yu X, Roehl R, Yeh J, Gashti S, Antenor J, et al. Serum PSA correlates more strongly with percentage of cancer and cancer volume than with prostate size. J Urol. 2005;173 Suppl 4:257.
13. Ochiai A, Babaian R. Update on prostate biopsy technique. Curr Opin Urol. 2004;14:157-62.
14. Punglia R, D'Amico A, Catalona W, Roehl K, Kuntz K. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003;349:335-42.
15. Mikolajczyk S, Song Y, Wong JR, Matson R, Rittenhouse H. Are multiple markers the future of prostate cancer diagnostics? Clin Biochem. 2004;37:519-28.
16. Lein M, Semejonow A, Graefen M, Kwiatkowoski M, Abramjuk C, Stephan C, et al. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol. 2005;174:2150-3.
17. Khan M, Sokoll L, Chan D, Mangold L, Mohr P, Mikolajczyk S, et al. Clinical utility of proPSA and bening PSA when percent free PSA is less yhan 15%. Urology. 2004;64:1160-4.
18. Hessels D, Rittenhouse H, Schalken J. Molecular diagnosis in prostate cancer. Eur Urol Update Series. 2005;3:200-13.
19. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64:311-5.
20. Hessels D, Gunnewiek K, VanOort I, Karthaus H, VanLeenders G, VanBalken B. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8-15.
21. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol. 2004;46:182-6.